Dyslipidemie

Cardiovascular diseases (CVDs) are the leading cause of death globally

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Praluent: artsenverklaring

Praluent Zorgservice

Praluent: peninstructie video's

In de video's wordt duidelijk uitgelegd hoe de pen te gebruiken - voor beide doseringen.

Preventive Cardiology: Key Insights from Professor Michal Vrablik

Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262